"Kicking off the proteomics track at the Beyond Genome conference here today, Stephen Naylor from MIT's CSBi program introduced a number of challenges he sees facing proteomics scientists.
The good news, he noted, is that proteomics is getting more attention from more researchers, noting that the majority of talks and papers at this year's ASMS meeting last month involved proteomics. He also assured conference attendees that there have been plenty of advances moving the field forward.
But there's some bad news too, he said, including what he called the "graveyard" of embattled or completely failed proteomics companies."
Businessweek From Proteins to Profits
" Proteomics is the study of human proteins, the building blocks of life -- and the culprits behind diseases. Oxford was arguably the first to tackle proteomics on a large scale."
" Now, the former chief of one of the world's largest pharmaceutical companies is trying to resurrect Oxford. Some six months ago, the board hired a new CEO, Dr. David Ebsworth, who used to run the worldwide pharmaceuticals operations of Bayer (BAY ), the German drug and chemical giant. Ebsworth has wasted no time in implementing changes. He has hired new management and broadened Oxford's focus to proteomics, cancer research, and a niche drug market known as "glyco-lipid storage disorders." The goal: profitability within three years."redux [12.06.02]
Genomeweb Proteomics Battens Down the Hatches
"In the twilight of 2002, the proteomics flame is a mere glimmer. The term has devolved from buzzword to dirty word, and VCs have grown skeptical of p-word business models."
"Proteome players are also fighting a backlash. "There's a lot of singed hair and burnt fingers from some of the genomic endeavors, and big pharma is being more careful," says Affinium CEO John Mendlein."redux [11.22.02]
BioMedNet The human proteome - a global challenge
[requires 'free' registration]
"The Human Proteome Organization (HUPO), which will tomorrow launch its first world congress, faces the unique challenge of bringing together the public and private sectors in a coordinated global research effort aimed at mining the human proteome, says HUPO president Sam Hanash.
Contributing to that effort are researchers in Europe, Asia-Oceania, and North America. "We are witnessing a tremendous interest in proteomics on the part of countries that a decade ago were not active in genomics and that may well become leaders in proteomics in a short time," said Hanash, an oncologist at the University of Michigan in Ann Arbor."redux [10.10.02]
The Seattle Times Seattle nonprofit lands $19.8 million for protein research
"The Institute for Systems Biology, a Seattle nonprofit research center led by gene-sequencing pioneer Dr. Leroy Hood, said yesterday it has landed a $19.8 million contract from the National Institutes of Health to advance understanding of proteomics, the study of how proteins interact in the body."
In the wake of recent breakthroughs unraveling the human genetic code, proteomics is increasingly being viewed by scientists as the next step. Scientists say genes provide the instructions for making proteins, and proteins carry out the real action inside the cell."redux [12.20.01]
BioMedNet Proteomics? Great label! (But what is it?)
[requires 'free' registration]
""Just because you use a protein doesn't make you a proteomics researcher," Joshua LaBaer, director of the Institute of Proteomics at Harvard Medical School, told BioMedNet News.
After the success of genomics, "everyone wants to think of proteomics as the next great science," but calling themselves proteomics researchers "is not really fair," LaBaer said. "A lot of people who claim to do genomics aren't genomic researchers either," he added. "They are just studying gene sequences.""redux [12.12.01]
Science High-Speed Biologists Search for Gold in Proteins
[ summary can be viewed for free once registered ]
"Proteomics aims to chart the ebb and flow of tens of thousands of proteins at once to produce snapshots of life inside cells. The technology to pull it off doesn't exist yet, however, and the competition is stiff for those proteins that can be nabbed using current methods. But this young field is growing up fast. This special News Focus looks at the promise and roadblocks of biology's latest wellspring. The package includes profiles of GeneProt, the biggest proteomics test-bed to date, and Stephen Burley , a crystallographer who is leaving academia to direct research at a small start-up company. Other stories discuss the potential of protein chips for new diagnostics and research tools and the problems faced by companies attempting to patent proteins."redux [08.15.01]
GenomeWeb Study Foresees Proteomics Market Growing to $5.6B by 2006
"A new study of the proteomics market forecast that the proteomics market would grow nearly six-fold to $5.6 billion by 2006 from $963 million in 2000.
In its report, consultancy firm Frost & Sullivan said the increase would be driven by a shift towards the analysis of proteomes following the discovery that the human genome contains fewer genes than originally predicted.
"Proteomics adds value to drug discovery by charting the distribution of proteins, identifying and characterizing proteins of interest, and elucidating the participation of proteins in biochemical pathways boosting the number of potential targets around which lead compounds can be designed and screened," Eric Gay, a Frost & Sullivan analyst, said in a statement."redux [07.11.01]
Scientific American The Post-Genome Project
"Their bold proclamation has raised a few eyebrows in the scientific community. "It's easy to say that you'll complete a comprehensive proteome map," notes Marc Vidal of the Dana-Farber Cancer Institute in Boston. "But none of us knows what that means." There may be only one genome, but when it comes to the proteome, different proteins can be more or less active in different cells at different times during development, under different physiological conditions or in different disease states. The proteome's nature "makes it hard to define what we're doing--not just Myriad, but all of us," remarks Joshua LaBaer, director of the Institute of Proteomics at Harvard Medical School. "There's no such thing as a human proteome," adds Keith L. Williams, CEO of Proteome Systems, headquartered in Sydney, Australia. Look at the liver, for example, he says: "After a glass of red wine, you'll have a different proteome."redux [06.20.01]
Forbes Proteins Are Back To Confuse Investors
"Scientists thought about trying to catalogue all the proteins in the body a decade ago.
But it seemed impossible, and was therefore impossible to fund. Researchers moved on to the much simpler job of sequencing the human genome.
They were right to do so. Cataloguing proteins turns out to be downright confusing. Lately, more and more biotech companies are entering a field they call "proteomics," an ugly word searching for a focus group."redux [03.13.01]
The Scientist Is a Human Proteome Project Next?
[requires 'free' registration]
"A commonly expressed opinion is that a single Human Proteome Project can never match HGP's success. Eric S. Lander , director of the Whitehead Center for Genome Research in Cambridge, Mass., notes that biologists simply don't know how to characterize the proteome "from end to end, nailing every protein. The tools are not ready. And it's not clear that [such a project] makes sense." He contrasts proteomics to HGP where "there is a certain fixed number of base pairs--about three billion--and we were going to get them all. And so it had a beginning and an end to it."redux [01.31.01]
GenomeWeb Proteomics Effort Shouldn't Mimic Genome Project, Experts Say
"Can sequencing do for the proteome what it did for the genome?
On Wednesday, a number of world-renowned researchers in the field of proteomics issued a resounding " no."
"When a company has phenomenal success with strategy A, you want to do strategy A on the next subject," said John Richards, a professor of organic and biochemistry at California Institute of Technology, referring to current corporate attempts to map the proteome.
"This doesn't work," he said."
“Bioinformatics will be at the core of biology in the 21st century. In fields ranging from structural biology to genomics to biomedical imaging, ready access to data and analytical tools are fundamentally changing the way investigators in the life sciences conduct research and approach problems. Complex, computationally intensive biological problems are now being addressed and promise to significantly advance our understanding of biology and medicine. No biological discipline will be unaffected by these technological breakthroughs.”BIOINFORMATICS IN THE 21st CENTURY
the panda's thumb
bioinformatics.org / nodalpoint / flags and lollipops / on genetics / a bioinformatics blog / andrew dalke / the struggling grad student / in the pipeline / gene expression / free association / pharyngula / the personal genome / genetics and public health blog / the medical informatics weblog / linuxmednews / nanodot / complexity digest /
nsu / nyt science / bbc scitech / newshub / biology news net /
informatics review / stanford / bmj info in practice / bmj info in practice /
look snazzy and support the site at the same time by buying some snowdeal schwag !
valid xhtml 1.0?
This site designed by
Eric C. Snowdeal III .